November 2011 Dr. Redonna K. Chandler of NIDA receives the Institute's 2011 Innovator Award for developing a method that fosters collaboration and data sharing on various studies of HIV in criminal justice populations.
April 2009 Highlights a project in which nine research centers collaborate with criminal justice partners to test science-based tools for integrating drug abuse treatment in prisons and probation and parole programs.
March 2008 Presents an update on NIDA’s Southern African Initiative, a program that aims to build research capacity and infrastructure in the area of addiction, particularly drug-related HIV transmission.
February 2013 Despite the advances in treatment and prevention, roughly 50,000 new HIV infections still occur annually in the Nation. Research, in large part supported by NIDA, has produced a strategy to address this circumstance and break the epidemiological impasse: seek out HIV-infected individuals, particularly those in “hard-to-reach” groups that have minimal contact with the health care system; offer them HIV testing and treatment; and provide support to help them stay in treatment.
November 2014 Methamphetamine use and HIV infection raise the risk for functional dependence, or the need for assistance with everyday tasks. People who use methamphetamine and are HIV positive showed the highest levels of functional dependence in most domains of daily life.
April 2013 Patients were more likely to take a rapid HIV test when substance abuse treatment programs offered the test onsite rather than referred for offsite testing. Patients were equally likely to accept and learn their HIV status whether the offer of onsite testing was accompanied by 30 minutes of risk reduction counseling or by 5 minutes of brief information on the testing procedure. Onsite testing accompanied by brief information was cost effective, taking into account the projected lifetime costs of treatment and the gains in health and longevity for detected cases.
December 2009 Reports finding from a study showing that access to antiretroviral therapies, HAART in particular, can improve the health of HIV-infected patients who have a history of injection drug use.